Buscar resultados de ensayos clínicos
Chronic Graft Versus Host Disease - 29 Studies Found
Estado | Estudiar |
Completed |
Nombre del estudio: Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease Condición: Oral Chronic Graft-versus-host Disease Fecha: 2008-05-27 Intervenciones:
|
Withdrawn |
Nombre del estudio: Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease Condición: Active Chronic Graft Versus Host Disease Fecha: 2009-10-26 Intervenciones: Drug: Pentostatin; Cyclophosphamide; Rituximab Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophospha |
Active, not recruiting |
Nombre del estudio: Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Condición: Chronic GVHD Fecha: 2010-04-16 Intervenciones:
|
Recruiting |
Nombre del estudio: Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD) Condición: Refractory Chronic Graft Versus Host Disease (cGVHD) Fecha: 2015-01-14 Intervenciones: Device: Photopheresis Theraflex ECP™ The Macopharma (Theraflex ECP™) approach is based on a |
Recruiting |
Nombre del estudio: Treatment of Chronic GVHD of Liver or Lungs by ECP Condición: Chronic Graft-Versus Host Disease Fecha: 2006-01-03 Intervenciones: Procedure: Extracorporeal photoimmunotherapy |
RECRUITING |
Nombre del estudio: A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. Condición: Chronic Graft Versus Host Disease Fecha: 2024-05-18 Intervenciones: Pharmaceutical form:Tablet-Route of administration:oral |
RECRUITING |
Nombre del estudio: Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease Condición: Chronic Graft Versus Host Disease Fecha: 2024-05-18 Intervenciones: Given PO |
NOT_YET_RECRUITING |
Nombre del estudio: Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease Condición: Chronic Graft Versus Host Disease Fecha: 2024-05-18 Intervenciones: 200mg PO QD x 24 cycles (28-day cycle) |
COMPLETED |
Nombre del estudio: Abatacept to Treat Steroid Refractory Chronic Graft Versus Host Disease (cGVHD) Condición: Chronic Graft Versus Host Disease Fecha: 2024-05-18 Intervenciones: The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose l |